Pharmaceutical dosage forms

1. A pharmaceutical dosage form for oral administration comprising

(a) the drug substance 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile as defined by formula (1)

or any pharmaceutically acceptable salt thereof, and

(b) 70% to 95% by weight of microcrystalline cellulose based on the total weight of said pharmaceutical dosage form.

2. The pharmaceutical dosage form according to claim 1 , wherein said drug substance is present as phosphate salt.

3. The pharmaceutical dosage form according to claim 1 , wherein said drug substance, calculated based on its free base, is present from 0.5 to 20% by weight based on the total weight of said pharmaceutical dosage form.

4. The pharmaceutical dosage form according to claim 1 further comprising a glidant.

5. The pharmaceutical dosage form according to claim 4 wherein said glidant is present from 0.1 to 5% by weight based on the total weight of said pharmaceutical dosage form.

6. The pharmaceutical dosage form according to claim 1 comprising

(a) the drug substance 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile present as phosphate salt,

(b) 70% to 95% by weight of microcrystalline cellulose based on the total weight of said pharmaceutical dosage form, and

(c) colloidal silicon dioxide.

7. The pharmaceutical dosage form according to claim 6 comprising:

(a) 1-8%, calculated based on its free base, by weight of the drug substance 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile present as monophosphate salt,

(b) 70-95% by weight of the microcrystalline cellulose,

(c) 0.3-1.5% by weight of the colloidal silicon dioxide, based on the total weight of said pharmaceutical dosage form.

8. The pharmaceutical dosage form according to claim 1 further comprising mannitol.

9. The pharmaceutical dosage form according to claim 8 wherein said mannitol is present from 3 to 40% by weight based on the total weight of said pharmaceutical dosage form.

10. The pharmaceutical dosage form according to claim 1 comprising:

(a) 4±1%, calculated based on its free base, by weight of the drug substance 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile present as monophosphate salt,

(b) 77±7% by weight of the microcrystalline cellulose,

(c) 0.6±0.2% by weight of the colloidal silicon dioxide,

(d) 10±2% by weight of mannitol,

and optionally further comprising:

(e) 2±0.5% by weight of a disintegrant, and

(f) 1.5±0.5% by weight of a lubricant

based on the total weight of said pharmaceutical dosage form.

11. A process for the preparation of a pharmaceutical dosage form as defined by claim 1 comprising blending the drug substance 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile with microcrystalline cellulose.

12. The process according to claim 11 wherein the blending of the drug substance with microcrystalline cellulose is performed as a first process step before any sieving, screening, compaction, or compression step.

13. The process according to claim 11 further comprising the use of a glidant to prepare a blend which is ready for tabletting.

14. The process according to claim 11 further characterized by the following process steps:

(1) blending the drug substance together with microcrystalline cellulose, and optionally further ingredients such as a glidant, a disintegrant, and a lubricant, to obtain a machine-compactable blend,

(2) compacting the machine-compactable blend by dry granulation, preferably by roller compaction, to obtain a compacted material,

(3) blending the compacted material with colloidal silicone dioxide, and optionally with further ingredients such as microcrystalline cellulose, mannitol, a disintegrant, and a lubricant, to obtain a machine-compressible blend,

(4) compressing the machine-compressible blend by use of a tabletting machine to obtain tablets.

15. The pharmaceutical dosage form according to claim 2 , wherein said drug substance is present as a mono-phosphate salt.

16. The pharmaceutical dosage form according to claim 4 wherein said glidant is a silicon dioxide.

17. The pharmaceutical dosage form according to claim 16 wherein said silicon dioxide is a colloidal silicon dioxide.

18. The pharmaceutical dosage form according to claim 9 wherein said mannitol is present from 5 to 40% by weight based on the total weight of said pharmaceutical dosage form.

19. The pharmaceutical dosage form according to claim 10 wherein said disintegrant is croscarmellose sodium.

20. The pharmaceutical dosage form according to claim 10 wherein said lubricant is magnesium stearate.